Lung Cancer New England Journal

Lung Cancer New England Journal

The links below contain various information about Lung Cancer New England Journal that might interest you. The links below contain various information about the keyword that might interest you. Review information from various sources to form a position based on as much information as possible.


Lung Cancer | NEJM - New England Journal of Medicine

    https://www.nejm.org/doi/full/10.1056/NEJMra0802714
    Lung cancer is the leading cause of cancer deaths in the United States 1 and worldwide. The two major forms of lung cancer are non–small-cell lung cancer (about 85% of all lung cancers) and ...

Sotorasib for Lung Cancers with KRAS p.G12C Mutation | …

    https://www.nejm.org/doi/full/10.1056/NEJMoa2103695
    Original Article from The New England Journal of Medicine — Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Reduced Lung-Cancer Mortality with Volume CT …

    https://www.nejm.org/doi/full/10.1056/NEJMoa1911793
    At 10 years of follow-up, 156 men with a known date of lung-cancer diagnosis in the screening group and 206 in the control group had died from lung cancer (2.50 deaths per 1000 person-years and 3 ...

The New England Journal of Medicine (NEJM): Lung Cancer

    https://nejm-journals.blogspot.com/2009/01/lung-cancer.html
    The New England Journal of Medicine (NEJM). Lung Cancer 10:13 ... (Sept. 25 issue)1 note, “Smoking causes all types of lung cancer but is most strongly linked with small-cell lung cancer and squamous-cell carcinoma.” In the legend to Figure 1, they also note, “Most tumors that are not related to smoking are adenocarcinomas and develop in ...

Early Palliative Care for Patients with Metastatic Non ...

    https://www.nejm.org/doi/pdf/10.1056/NEJMoa1000678
    The new england journal of medicine n engl j med 363;8 nejm.org august 19, 2010 733 original article Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell …

    https://pubmed.ncbi.nlm.nih.gov/31562796/
    Background: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in …

First-Line Lorlatinib or Crizotinib in Advanced ALK ...

    https://pubmed.ncbi.nlm.nih.gov/33207094/
    Background: Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non-small-cell lung cancer (NSCLC).The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear.. Methods: We conducted a global, …

Pembrolizumab plus Chemotherapy in Metastatic Non …

    https://pubmed.ncbi.nlm.nih.gov/29658856/
    Background: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice.

Home Page: Lung Cancer

    https://www.lungcancerjournal.info/
    Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, …

We are sure that you have received all the information you are interested in about Lung Cancer New England Journal. We recommend that you also look at data on similar issues related to journalism.

Related Pages

New Pages

Previous Page | Next Page